NCT01404585已完成2 期
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BMS-817399 in Adults With Active, Moderate to Severe Rheumatoid Arthritis and Inadequate Response to Methotrexate
Bristol-Myers Squibb6 个研究点 分布在 2 个国家目标入组 123 人开始时间: 2011年9月最近更新:
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 123
- 试验地点
- 6
- 主要终点
- Disease Activity Score using 28 joint count and C Reactive Protein (DAS28-CRP) change from baseline of BMS-817399 versus placebo
研究概览
简要总结
The purpose of this study is to assess whether BMS-817399 in combination with Methotrexate is effective in treating moderate to severe rheumatoid arthritis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female subjects, 18 years of age or older, with rheumatoid arthritis (RA) for at least 6 months prior to screening
- •Subjects must have a tender joint count of at least 6 (28 joint count), swollen joint count of at least 6 (28 joint count) at screening. All subjects must have clinical evidence of synovitis in one hand/wrist at screening
- •Serum C-reactive protein (hsCRP) above upper limits of normal at screening
- •Subjects must have been treated with and tolerated Methotrexate (MTX) therapy at a weekly oral or parenteral dose ≥ 10 mg for ≥ 4 months prior to screening. Dose must be stable, with no change in route of administration, for ≥ 6 weeks prior to randomization. A MTX weekly dose as low as 7.5 mg is permitted if intolerance to doses ≥10 mg has been documented in the subject's medical history
- •Subjects must be receiving folic acid, folinic acid, or leucovorin supplementation at a stable dose for at least 4 weeks prior to randomization
- •Subjects who were previously treated with up to two tumor necrosis factor α (TNF-α) inhibitors
- •If taking antimalarials (e.g. hydroxychloroquine or chloroquine), subject must have been on a stable dose for ≥ 4 months prior to randomization
- •If taking non-steroidal anti-inflammatory drugs (NSAIDs), subjects must have been on stable doses for ≥ 2 weeks prior to randomization
- •If taking oral corticosteroids, daily doses must be ≤ 10 mg/day of prednisone or equivalent and stable for ≥ 4 weeks before randomization
- •Subject is willing to participate to the study and has signed the informed consent prior to undergoing any screening procedures
- •Women of childbearing potential (WOCBP) and men must agree to use at least two acceptable methods to avoid pregnancy for the entire study period and until 60 days (for women) and 90 days (for men) after the last dose of BMS-
- •WOCBP must have a negative urine pregnancy test at screening, randomization and at scheduled visits throughout the study
排除标准
- •Arthritis onset prior to 16 years of age or subjects with documented juvenile RA
- •Subjects who are bed- or wheelchair-bound
- •Subjects with other autoimmune diseases or arthritis syndromes
- •Women who are pregnant, breastfeeding or with a positive pregnancy test at screening or prior to randomization
- •Subjects who have any condition that could impact upon the absorption of study drug (i.e., gastric stapling, duodenal surgery, malabsorption syndrome)
- •Subjects with a history of, or a concurrent severe, progressive, or uncontrolled disease (other than RA) that in the opinion of the investigator might place the subject at unacceptable risk for participation in this study
- •Subjects who have present or previous (last 5 years) malignancies, except history of cured squamous or basal skin cell carcinoma or cured breast or cervical cancer
- •Subjects at risk for tuberculosis (TB) or with evidence of TB clinical history, chest X rays or tuberculin skin test
- •Subjects with evidence of active or latent bacterial or viral infections (including human immunodeficiency virus); Positive blood screen for hepatitis B surface antigen or hepatitis C antibody
- •Subjects with any serious bacterial infection within the last 2 months, unless treated and resolved with antibiotics
- •Subjects who have clinically significant drug or alcohol abuse or known cirrhosis including alcoholic cirrhosis
- •If a subject has received any of the following treatments, the indicated washout period prior to randomization must be followed:
- •Oral or injectable azathioprine, gold, D-Penicillamine, cyclosporine, anakinra, etanercept, parenteral or intra-articular corticosteroids: 30 days
- •Leflunomide: 6 months unless an active washout with Cholestyramine has been performed
- •Mycophenolate mofetil, cyclophosphamide, tacrolimus or other immunosuppressant: 3 months
- •Adalimumab, Infliximab, Golimumab, Certolizumab pegol, Abatacept or Tocilizumab: 60 days
- •Rituximab or any B-cell depleting agent: 1 year
- •Use CYP3A4 inhibitors or inducers during the study
- •Subjects with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ 1.5x upper limit of normal (ULN), total bilirubin ≥ 1.4x ULN, estimated glomerular filtration rate (GFR) < 50 mL/min/1.73m2, hemoglobin < 10.0 g/dL, white blood cell count < 3,500/mm3, absolute neutrophil count < 1,700/mm3 or platelets < 125,000/mm3
研究组 & 干预措施
Arm 1: Placebo
Placebo Comparator
干预措施: Placebo (Drug)
Arm 2: BMS-817399 (200 mg)
Experimental
干预措施: BMS-817399 (Drug)
Arm 3: BMS-817399 (400 mg)
Experimental
干预措施: BMS-817399 (Drug)
结局指标
主要结局
Disease Activity Score using 28 joint count and C Reactive Protein (DAS28-CRP) change from baseline of BMS-817399 versus placebo
时间窗: Baseline and at 12 weeks
次要结局
- Safety assessments will be based on adverse event reports and the results of vital sign measurements, electrocardiogram, physical examinations, and clinical laboratory tests(16 weeks)
- Proportion of subjects achieving 20% American College of Rheumatology (ACR) response in each treatment group(Day 15)
- Proportion of subjects achieving 20% ACR response in each treatment group(Day 85)
- Percent change from baseline in disability index of the Health Assessment Questionnaire (HAQ-DI)(Baseline and Day 85)
- To assess the minimum observed concentration (Cmin) of BMS-817399(Day 15, Day 29, Day 57 and Day 85)
- Proportion of subjects achieving 70% ACR response in each treatment group(Day 85)
- Proportion of subjects achieving 50% ACR response in each treatment group(Day 85)
研究者
研究点 (6)
Loading locations...
相似试验
已完成
1 期
A Study to Assess the Effects of BMS-986371 on the Drug Levels of Methotrexate in the Presence and Absence of SulfasalazineHealthy ParticipantsNCT05445440Bristol-Myers Squibb30
已完成
4 期
A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)Rheumatoid ArthritisNCT01185288AbbVie (prior sponsor, Abbott)309
已完成
3 期
A Study of Safety and Efficacy Comparing ABT-874 Versus Methotrexate in Subjects With Moderate to Severe Plaque PsoriasisPsoriasisNCT00679731AbbVie (prior sponsor, Abbott)317
已完成
2 期
A Multiple Dose Study to Evaluate Subcutaneous AMG 108 in Subjects With Rheumatoid ArthritisRheumatoid ArthritisNCT00293826Amgen813
终止
2 期
A Study of the Use of Methotrexate in the Treatment of Chronic Idiopathic UrticariaUrticariaNCT00189878Barnsley Hospital3